Alopecia areata
CH Pratt, LE King, AG Messenger… - Nature reviews Disease …, 2017 - nature.com
Alopecia areata is an autoimmune disorder characterized by transient, non-scarring hair
loss and preservation of the hair follicle. Hair loss can take many forms ranging from loss in …
loss and preservation of the hair follicle. Hair loss can take many forms ranging from loss in …
Alopecia areata: a review of disease pathogenesis
Background Alopecia areata is a disorder that results in nonscarring hair loss. The
psychological impact can be significant, leading to feelings of depression and social …
psychological impact can be significant, leading to feelings of depression and social …
Two phase 3 trials of baricitinib for alopecia areata
Background Alopecia areata is an autoimmune condition characterized by rapid hair loss in
the scalp, eyebrows, and eyelashes, for which treatments are limited. Baricitinib, an oral …
the scalp, eyebrows, and eyelashes, for which treatments are limited. Baricitinib, an oral …
Tofacitinib for the treatment of severe alopecia areata and variants: a study of 90 patients
LY Liu, BG Craiglow, F Dai, BA King - Journal of the American Academy of …, 2017 - Elsevier
Background Alopecia areata (AA) is a common autoimmune disorder. There are no reliably
effective therapies for AA. Objective We sought to evaluate the safety and efficacy of the …
effective therapies for AA. Objective We sought to evaluate the safety and efficacy of the …
[HTML][HTML] Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: phase 2 results from a randomized controlled …
Background There are no treatments approved by the Food and Drug Administration for
alopecia areata. Objective To evaluate the efficacy and safety of baricitinib in patients with≥ …
alopecia areata. Objective To evaluate the efficacy and safety of baricitinib in patients with≥ …
Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure
Background Vitiligo is an autoimmune disease in which cutaneous depigmentation occurs.
Existing therapies are often inadequate. Prior reports have shown benefit of the Janus …
Existing therapies are often inadequate. Prior reports have shown benefit of the Janus …
Tofacitinib for the treatment of alopecia areata and variants in adolescents
BG Craiglow, LY Liu, BA King - Journal of the American Academy of …, 2017 - Elsevier
Background There are no reliably effective therapies for alopecia areata (AA). Objective We
sought to evaluate the benefit and adverse effects of the Janus kinase 1/3 inhibitor …
sought to evaluate the benefit and adverse effects of the Janus kinase 1/3 inhibitor …
[HTML][HTML] “'You lose your hair, what's the big deal?' I was so embarrassed, I was so self-conscious, I was so depressed:” a qualitative interview study to understand the …
Background Alopecia areata (AA) is characterized by hair loss that can affect the scalp and
body. This study describes the psychosocial burden of AA. Methods Participants diagnosed …
body. This study describes the psychosocial burden of AA. Methods Participants diagnosed …
Living with alopecia areata: an online qualitative survey study
L Davey, V Clarke, E Jenkinson - British Journal of Dermatology, 2019 - academic.oup.com
Background Living with alopecia areata (AA) totalis and universalis (collectively referred to
here as AA) involves unpredictable, sometimes rapid hair loss. There is currently no effective …
here as AA) involves unpredictable, sometimes rapid hair loss. There is currently no effective …
The role of micronutrients in alopecia areata: a review
JM Thompson, MA Mirza, MK Park, AA Qureshi… - American journal of …, 2017 - Springer
Alopecia areata (AA) is a common, non-scarring form of hair loss caused by immune-
mediated attack of the hair follicle. As with other immune-mediated diseases, a complex …
mediated attack of the hair follicle. As with other immune-mediated diseases, a complex …